Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs

Shiela M. Strauss, Corrine Munoz-Plaza, Nelson Jose Tiburcio, Janetta Astone-Twerell, Don C. Des Jarlais, Marya Gwadz, Holly Hagan, Andrew Osborne, Andrew Rosenblum

Research output: Contribution to journalArticle

Abstract

Given the high prevalence of hepatitis C virus (HCV) infection among drug users, HCV testing is critical in this population. While many drug treatment programs offer HCV testing, patients often do not utilize this essential program-facilitated service. Summarizing data collected in semi-structured interviews and surveys with patients in 25 programs, this paper identifies barriers and facilitators to being tested for HCV through the program. Barriers include the patient's belief that she/he is not HCV infected, fear of needles, fear of obtaining a positive HCV test result, fear of disclosure of such a result, and fear of inappropriate or disrespectful treatment during the testing process. In addition, 38% of HCV sero-unaware or sero-negative patients completing the survey did not know that HCV testing was offered through their programs. Salient facilitators for those tested through their programs include support from staff in explaining the importance of testing and help in understanding and coping with test results.

Original languageEnglish (US)
Pages (from-to)1161-1185
Number of pages25
JournalJournal of Drug Issues
Volume38
Issue number4
StatePublished - Sep 2008

Fingerprint

Hepacivirus
contagious disease
drug
Pharmaceutical Preparations
Fear
anxiety
Therapeutics
Disclosure
Virus Diseases
Drug Users
Needles
coping
Interviews
staff
interview
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Public Health, Environmental and Occupational Health
  • Medicine (miscellaneous)
  • Health(social science)

Cite this

Strauss, S. M., Munoz-Plaza, C., Tiburcio, N. J., Astone-Twerell, J., Des Jarlais, D. C., Gwadz, M., ... Rosenblum, A. (2008). Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. Journal of Drug Issues, 38(4), 1161-1185.

Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. / Strauss, Shiela M.; Munoz-Plaza, Corrine; Tiburcio, Nelson Jose; Astone-Twerell, Janetta; Des Jarlais, Don C.; Gwadz, Marya; Hagan, Holly; Osborne, Andrew; Rosenblum, Andrew.

In: Journal of Drug Issues, Vol. 38, No. 4, 09.2008, p. 1161-1185.

Research output: Contribution to journalArticle

Strauss, SM, Munoz-Plaza, C, Tiburcio, NJ, Astone-Twerell, J, Des Jarlais, DC, Gwadz, M, Hagan, H, Osborne, A & Rosenblum, A 2008, 'Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs', Journal of Drug Issues, vol. 38, no. 4, pp. 1161-1185.
Strauss SM, Munoz-Plaza C, Tiburcio NJ, Astone-Twerell J, Des Jarlais DC, Gwadz M et al. Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. Journal of Drug Issues. 2008 Sep;38(4):1161-1185.
Strauss, Shiela M. ; Munoz-Plaza, Corrine ; Tiburcio, Nelson Jose ; Astone-Twerell, Janetta ; Des Jarlais, Don C. ; Gwadz, Marya ; Hagan, Holly ; Osborne, Andrew ; Rosenblum, Andrew. / Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs. In: Journal of Drug Issues. 2008 ; Vol. 38, No. 4. pp. 1161-1185.
@article{e78e156beb0c41959f9ae467ce442a9d,
title = "Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs",
abstract = "Given the high prevalence of hepatitis C virus (HCV) infection among drug users, HCV testing is critical in this population. While many drug treatment programs offer HCV testing, patients often do not utilize this essential program-facilitated service. Summarizing data collected in semi-structured interviews and surveys with patients in 25 programs, this paper identifies barriers and facilitators to being tested for HCV through the program. Barriers include the patient's belief that she/he is not HCV infected, fear of needles, fear of obtaining a positive HCV test result, fear of disclosure of such a result, and fear of inappropriate or disrespectful treatment during the testing process. In addition, 38{\%} of HCV sero-unaware or sero-negative patients completing the survey did not know that HCV testing was offered through their programs. Salient facilitators for those tested through their programs include support from staff in explaining the importance of testing and help in understanding and coping with test results.",
author = "Strauss, {Shiela M.} and Corrine Munoz-Plaza and Tiburcio, {Nelson Jose} and Janetta Astone-Twerell and {Des Jarlais}, {Don C.} and Marya Gwadz and Holly Hagan and Andrew Osborne and Andrew Rosenblum",
year = "2008",
month = "9",
language = "English (US)",
volume = "38",
pages = "1161--1185",
journal = "Journal of Drug Issues",
issn = "0022-0426",
publisher = "Journal of Drug Issues Inc.",
number = "4",

}

TY - JOUR

T1 - Barriers and facilitators to undergoing hepatitis C virus (HCV) testing through drug treatment programs

AU - Strauss, Shiela M.

AU - Munoz-Plaza, Corrine

AU - Tiburcio, Nelson Jose

AU - Astone-Twerell, Janetta

AU - Des Jarlais, Don C.

AU - Gwadz, Marya

AU - Hagan, Holly

AU - Osborne, Andrew

AU - Rosenblum, Andrew

PY - 2008/9

Y1 - 2008/9

N2 - Given the high prevalence of hepatitis C virus (HCV) infection among drug users, HCV testing is critical in this population. While many drug treatment programs offer HCV testing, patients often do not utilize this essential program-facilitated service. Summarizing data collected in semi-structured interviews and surveys with patients in 25 programs, this paper identifies barriers and facilitators to being tested for HCV through the program. Barriers include the patient's belief that she/he is not HCV infected, fear of needles, fear of obtaining a positive HCV test result, fear of disclosure of such a result, and fear of inappropriate or disrespectful treatment during the testing process. In addition, 38% of HCV sero-unaware or sero-negative patients completing the survey did not know that HCV testing was offered through their programs. Salient facilitators for those tested through their programs include support from staff in explaining the importance of testing and help in understanding and coping with test results.

AB - Given the high prevalence of hepatitis C virus (HCV) infection among drug users, HCV testing is critical in this population. While many drug treatment programs offer HCV testing, patients often do not utilize this essential program-facilitated service. Summarizing data collected in semi-structured interviews and surveys with patients in 25 programs, this paper identifies barriers and facilitators to being tested for HCV through the program. Barriers include the patient's belief that she/he is not HCV infected, fear of needles, fear of obtaining a positive HCV test result, fear of disclosure of such a result, and fear of inappropriate or disrespectful treatment during the testing process. In addition, 38% of HCV sero-unaware or sero-negative patients completing the survey did not know that HCV testing was offered through their programs. Salient facilitators for those tested through their programs include support from staff in explaining the importance of testing and help in understanding and coping with test results.

UR - http://www.scopus.com/inward/record.url?scp=62549147800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62549147800&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:62549147800

VL - 38

SP - 1161

EP - 1185

JO - Journal of Drug Issues

JF - Journal of Drug Issues

SN - 0022-0426

IS - 4

ER -